Logo

Novartis In-Licenses BieGene's Tislelizumab to Expand its Oncology Portfolio

Share this

Novartis In-Licenses BieGene's Tislelizumab to Expand its Oncology Portfolio

Shots:

  • BieGene to receive $650M up front- $1.55M as milestones along with royalties and retain rights to Tislelizumab in China & other countries. BeiGene has the option to co-detail Tislelizumab in NA
  • Novartis to get the development & commercialization rights to Tislelizumab in the US- Canada- Mexico- EU- UK- Norway- Switzerland- Iceland- Liechtenstein- Russia- & Japan. Additionally- the companies have identified multiple Tislelizumab + Novartis’ therapy combination clinical trials in solid tumors
  • Both parties have the freedom to conduct combination trials globally. Tislelizumab is an anti-PD-1 mAb- its 15 registration-enabling clinical trials underway in NSCLC and other solid tumors

 ­ Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions